Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

Metallibure

From Wikipedia, the free encyclopedia
Metallibure
Clinical data
Trade namesAimax, Suisynchron, Turisynchron
Other namesMethallibure; Methallibur; ICI-33828; AY-61122; NSC-69536
Drug classAntigonadotropin
Identifiers
  • 1-But-3-en-2-yl-3-(methylcarbamothioylamino)thiourea
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.011.952 Edit this at Wikidata
Chemical and physical data
FormulaC7H14N4S2
Molar mass218.34 g·mol−1
3D model (JSmol)
  • CC(C=C)NC(=S)NNC(=S)NC
  • InChI=1S/C7H14N4S2/c1-4-5(2)9-7(13)11-10-6(12)8-3/h4-5H,1H2,2-3H3,(H2,8,10,12)(H2,9,11,13)
  • Key:CGFFKDRVHZIQHL-UHFFFAOYSA-N

Metallibure (INNTooltip International Nonproprietary Name; also known as methallibure (USANTooltip United States Adopted Name, BANTooltip British Approved Name) or methallibur (German); brand names Aimax, Suisynchron, Turisynchron; former developmental codes ICI-33828, AY-61122, NSC-69536) is a medication which was introduced in 1973 and has been used in veterinary medicine to synchronize estrus.[1][2] It was withdrawn in the United States and Europe due to teratogenicity and has been replaced with altrenogest (Regumate, Matrix), a progestin.[2][3]

The precise mechanism of action of metallibure is unknown.[2] It has been described as a "nonsteroidal antigonadotropin" and it appears to act directly on the pituitary gland and/or hypothalamus to suppress gonadotropin secretion.[2] However, metallibure has also been reported to be an antiprogestogen and to act specifically via inhibition of the biosynthesis or secretion of progesterone.[4]

Metallibure has similar endocrinological effects in women.[5] It is associated with several unpleasant side effects including appetite loss, nausea, occasional vomiting, lethargy, and drowsiness.[5] Animal toxicity studies revealed that the medication induced the development of cataracts, and this resulted in the termination of its clinical development.[5]

See also

[edit]

References

[edit]
  1. J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 781–. ISBN 978-1-4757-2085-3.
  2. 1 2 3 4 I. Gordon (22 October 2013). Controlled Breeding in Farm Animals. Elsevier. pp. 313–. ISBN 978-1-4832-8569-6.
  3. Brüssow KP, Schneider F, Kanitz W, Rátky J, Kauffold J, Wähner M (2009). "Studies on fixed-time ovulation induction in the pig". Soc Reprod Fertil Suppl. 66: 187–95. PMID 19848281.
  4. A. Labhart (6 December 2012). Clinical Endocrinology: Theory and Practice. Springer Science & Business Media. pp. 523–. ISBN 978-3-642-96158-8.
  5. 1 2 3 JUCKER (21 December 2013). Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques. Birkhäuser. pp. 102–. ISBN 978-3-0348-7065-8.